On 15th December, the Cancer Drug Fund expert panel will be meeting to review a number of drugs currently on their list. Sadly Abraxane is one of the drugs to be reviewed.
We need you to write to your MP to explain why pancreatic cancer patients deserve to have access to this drug, which is the biggest breakthrough for the treatment of advanced pancreatic cancer in over 17 years
Please e-mail or write to your MP today. We have drafted the following letter that you can use if you wish. You can find your local MP and contact details here.
As a member of your constituency, I am writing to you to seek your assistance with an urgent matter relating to a meeting to be held by The Cancer Drugs Fund Panel on 15th December.
As I’m sure you are aware, the panel are meeting to re-evaluate a number of drugs on their list. This includes Abraxane, which is the biggest breakthrough for the treatment of advanced pancreatic cancer in over 17 years.
This is a matter incredibly close to my heart. [insert your personal story here]
While I understand that the CDF have a limited budget and they are under pressure to reduce costs, I do hope they consider how important it is to keep Abraxane on the list considering how little treatment is available to pancreatic cancer patients.
With this disease, patients and families have very little hope as it is. Currently, pancreatic cancer only has a 3% survival rate and an average life expectancy of 4-6 months from diagnosis.
Clinical trials of Abraxane in combination with gemcitabine have shown that patients on average will face an extra 2.1 more months survival.
While that doesn’t sound significant, 2.1 months is an average figure – some patients involved in the trial lived more than 2 years. Abraxane could potentially double the number of patients who live two years or more (in comparison to those receiving gemcitabine alone). That is the potential hope this drug can give patients.
The standard treatment for pancreatic cancer is the use of gemcitabine alone. Only 10% of patients will respond to the treatment, rendering it next to useless for the majority. Far more people respond to Abraxane in combination with gemcitabine, offering the hope that this treatment could really have an impact on improved survival.
Please help by contacting David Cameron, Jeremy Hunt, Peter Clark, chair of CDF panel, and Simon Stevens, CEO of NHS England, urgently to explain to them why it’s vital that pancreatic cancer patients have continued access to Abraxane through the CDF.
I would like to take this opportunity to thank you for taking the time to read this and I would be happy to talk to you about this further either over the phone or in person.
I look forward to your response.